<DOC>
	<DOCNO>NCT00637221</DOCNO>
	<brief_summary>This open label exploratory study investigate safety effect single dose NPL-2009 ( 50 mg - 150 mg ) Prepulse Inhibition ( PPI ) Tests Continuous Performance Tasks ( CPT ) adult Fragile X Syndrome</brief_summary>
	<brief_title>Open Label Study Investigating Safety Efficacy NPL2009 50 mg - 150 mg Prepulse Inhibition Tests Continuous Performance Tasks , Adults With Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Male female patient , 18 45 year age . Diagnosis Fragile X Syndrome . Females must demonstrate negative pregnancy test screening . Females childbearing potential must use medically accept mean contraception must remain abstinent duration study . Each Legally Authorised Representative ( LAR , usually parent caregiver ) must level understanding sufficient provide write informed consent require study test procedure . Each patient must consent/assent ( depend centerspecific procedure ) require study test procedure . Permitted concomitant medication must stable least 6 week prior enrollment . The following concomitant medication permit : psychostimulants , SSRIs , atypical antipsychotic , anticonvulsant liver induce effect , clonidine . Each patient must able swallow capsule ( 2 , 3 4 ) provide study . Current treatment anticonvulsant know induce liver enzymes e.g . depakote Current treatment NmethylDaspartate ( NMDA ) antagonists Current treatment tricyclic antidepressant Current treatment typical antipsychotic Current treatment lithium Patients plan commence cognitive behaviour therapy period study begin cognitive behavioural therapy within 6 week prior enrolment . History , current cardiovascular , renal , hepatic , respiratory particularly gastrointestinal disease may interfere absorption , distribution , metabolism excretion study medication . History , current cerebrovascular disease brain trauma . History , current significant endocrine disorder , e.g . hypo hyperthyroidism . History , current malignancy . Presence psychotic symptom lifetime history schizophrenia , bipolar disorder , psychotic disorder , assess Investigator . Current major depressive disorder ( patient must free disorder 3 month prior enrolment ) . Judged clinically risk suicide ( suicidal ideation , severe depression , factor ) , assess Investigator . Tourette 's Disorder . Female patient either pregnant nursing . Current drug abuse dependence disorder dependency 3 month prior enrolment . Clinically significant abnormality safety laboratory test , vital sign EKG , measure screening Patients significant hear and/or visual impairment may affect ability complete test procedure Enrollment another clinical trial within previous 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
</DOC>